美国疾控中心1月5日发布备忘录，宣布不再将7种儿童疫苗列为"普遍推荐接种"疫苗。这些疫苗针 对轮状病毒、脑膜炎、甲肝、乙肝、流感、新冠和呼吸道合胞病毒。 邦塔批评疾控中心的决定"不负责且危险"。"削弱民众对疫苗的信心将导致接种率下降、传染病增 多，还会推高各州开支，包括医疗补助支出增加、新增用于辟谣和修订公共卫生指引的开支。" 肯尼迪2025年初受美国共和党籍总统特朗普任命正式出任卫生与公共服务部长。他曾多次发表反疫 苗言论，批评疾控中心等联邦卫生机构及其防疫措施，同时大幅裁减下属机构人员和经费，招致公共卫 生界广泛质疑。 新华社北京2月25日电 美国加利福尼亚州总检察长罗布·邦塔和亚利桑那州总检察长克丽丝·梅斯24 日宣布牵头一起由15个州参与的诉讼，指控联邦政府削减儿童疫苗接种计划违法，会增加疾病风险并使 各州不堪重负。这些州均为民主党人主政。 邦塔和梅斯等14州总检察长以及宾夕法尼亚州州长乔希·夏皮罗参与诉讼。他们在加州北区联邦地 区法院提交诉状，将美国卫生与公共服务部长小罗伯特·肯尼迪、疾病控制和预防中心代理主任杰伊·巴 塔查里亚以及两人所属机构列为被告。 据法新社24日报道，特朗普政府1月曾以其他国 ...

Core Viewpoint - The article discusses the significant decline in the stock prices of ten high-issue-price stocks in the A-share market, with seven of them falling below their issue prices, highlighting the risks associated with high valuations and market sentiment shifts [1][22]. Group 1: Stock Performance - Among the ten stocks, only Stone Technology, Naxin Micro, and BeiGene remain above their issue prices as of mid-February 2026 [6][8]. - The maximum decline from issue prices includes: - CanSino down 69.15% - Wanrun New Energy down 58.54% - Huabao New Energy down 54.93% - Yiqiao Shenzhou down 42.22% - Hemai down 32.82% - Foxit Software down 22.17% - Suocheng Technology down 12.83% [10]. - CanSino experienced a dramatic drop of 93% from its peak price of 797.20 yuan to 63.90 yuan [11][19]. Group 2: Company Backgrounds - Hemai, the highest issue price stock at 557.80 yuan, faced a significant decline after reaching a peak of 1877.43 yuan [12]. - Wanrun New Energy, listed at 299.88 yuan, never reached its issue price after its first day of trading [15]. - Yiqiao Shenzhou, with an issue price of 292.92 yuan, peaked at 353.83 yuan before falling to 73.38 yuan [16]. - CanSino, a COVID-19 vaccine stock, was listed at 209.71 yuan and peaked at 797.20 yuan before its decline [17]. Group 3: Market Conditions and Trends - The high issue prices were driven by market enthusiasm for sectors like hard technology, new energy, and biomedicine during the registration reform period from 2020 to 2023 [5][4]. - The overall market sentiment has shifted, leading to a decline in these stocks as the initial excitement waned [22]. - The article notes that the current new stock market shows a stark contrast, with a recent increase in participation and initial gains, but also warns of accumulating risks [24][26]. Group 4: Investment Implications - The high issue prices and P/E ratios of these stocks are no longer guarantees of company strength, but rather potential warning signs of investment risk [28]. - The article emphasizes that the era of easy profits from new stock subscriptions has ended, requiring more thorough research and disciplined investment strategies [27].

第四季度营收为6.78亿美元，高于市场预期的6.251亿美元，尽管同比下滑30%，但美国市场新冠疫苗销 售表现稳健，缓解了投资者对收入持续萎缩的担忧。公司同时重申2026年营收增长目标为10%，传递出 业务企稳信号。 财务状况 2025年全年运营支出预期下调至50亿-52亿美元，较此前指引缩减2亿美元；年末现金储备预计达81亿美 元，高于此前65亿-70亿美元的预测，增强了财务韧性。第四季度每股亏损2.11美元，较去年同期的2.91 美元收窄，反映亏损面收缩。 经济观察网莫德纳(MRNA.O)于2026年2月13日发布2025年第四季度及全年财报后，股价单日大幅上涨 7.58%，收盘报43.15美元，创下年内新高。当日成交额达5.14亿美元，量比1.61，换手率3.05%，显著高 于近期平均水平。 股价异动原因 当日纳斯达克指数上涨0.42%，生物技术板块涨幅1.85%，行业情绪向好。 资金面与技术面 低估值(市盈率TTM为负)与高波动性吸引短期资金流入，单日振幅达8.90%，成交量为近月均值的1.6 倍。 未来发展 流感疫苗审批受挫(FDA以临床试验设计问题拒审mRNA-1010)可能延迟2028年盈亏平衡 ...

Core Viewpoint - Moderna reported better-than-expected sales performance of its COVID-19 vaccine in the U.S., leading to fourth-quarter revenue exceeding Wall Street expectations [1][2]. Group 1: Financial Performance - The company's quarterly revenue was $678 million, surpassing the analyst average expectation of $626.1 million [2]. - Moderna has faced financial pressure due to a significant decline in COVID-19 vaccine demand following the pandemic [1]. Group 2: Future Outlook - The company reiterated its expectation for a 10% revenue growth in 2026 [2]. - Moderna is actively developing new products to fill the revenue gap and demonstrate the long-term viability of its mRNA technology [1].

来源 | 《财经》杂志 作者 | 《财经》记者 凌馨 编辑 | 王小 超跌之后的估值回归，是造就"X倍股"的最大因素 中国医药股领涨全球的2025年，涨幅最高的个股有哪些？ 香港市场，涌现出一批"三倍股""四倍股"，甚至"十倍股"，其中，有因产品海外授权交易声名鹊起的和铂医药、荣昌生物，也有2025年踩中了港股医药热点 的"打新宠儿"，还有一批，是经历了上一轮寒冬后，终于等来投资市场春天的老牌未盈利药企。 北海康成曾是"中国罕见病第一股"。它的产品，都是治疗普通人几乎没听说过的病。已经上市的两款产品，分别用于治疗黏多糖贮积症Ⅱ型、阿拉杰里综合 征以及进行性家族性胆汁淤积症。 因为主要针对罕见病市场，北海康成的产品市场都很小。2021年就在中国市场推出的首款产品，是用于治疗黏多糖贮积症Ⅱ型，至2024年末，共识别出843 名患者。另一款已上市产品，识别患者数为839名。 理论上，罕见病用药单价高，还可以享受药审、医保的各种政策倾斜，实际上，北海康成多年来仍处于亏损状态。2024年，全年收入8510.3万元，亏损金额 4.43亿元。截至2024年末，公司流动性资产4535.2万元，流动性负债4.826亿元。 北海 ...

Core Viewpoint - Pfizer's Q4 earnings report exceeded market expectations despite declining demand for COVID-related products, and the company reaffirmed its moderate guidance for 2026, which had previously raised investor concerns [1][2]. Financial Performance - Pfizer reported Q4 revenue of $17.56 billion, a slight year-over-year decline of approximately 1%, primarily due to decreased demand for COVID vaccines and the oral drug Paxlovid [1]. - COVID vaccine sales were $2.3 billion, down one-third year-over-year but above the $2 billion expectation; Paxlovid sales were $218 million, significantly below the $589 million forecast and down over two-thirds year-over-year [1]. - The company recorded a net loss of $1.65 billion for the quarter, translating to a loss of $0.29 per share, compared to a net profit of $410 million or $0.07 per share in the same period last year [2]. - Adjusted EPS for Q4 was $0.66, exceeding the market expectation of $0.57 [2]. Future Guidance - Pfizer maintained its 2026 guidance, projecting adjusted EPS between $2.80 and $3.00 and revenue of $59.5 billion to $62.5 billion, roughly flat compared to 2025 [2]. - The company anticipates a decline of approximately $1.5 billion in revenue from COVID products, expecting total sales for these products to drop to $5 billion [2]. - Loss of market exclusivity for several products, including Prevnar, is expected to contribute to an additional revenue decline of about $1.5 billion [2]. Market Competition and Pricing Strategy - Pfizer's CFO indicated that the 2026 guidance accounts for price compression and narrowing profit margins, as part of a drug pricing agreement with the U.S. government [2][3]. - Under this agreement, Pfizer will supply existing drugs to Medicaid patients at the lowest prices in other developed countries and provide equal "most favored nation" pricing for Medicare and commercial insurers [3]. New Product Development - To offset declining sales from COVID products and established drugs, Pfizer is investing in pipeline products, including a $10 billion acquisition of obesity biotech company Metsera [4]. - Initial data from Metsera's obesity injection showed significant weight loss effects, with participants losing up to 12.3% of their weight after 28 weeks [4]. - However, investor skepticism remains regarding whether this acquisition can compensate for the revenue shortfall from COVID vaccine and oral drug sales, especially in a market dominated by established players [4].

Core Viewpoint - The ongoing power struggle within Sinovac Biotech has led to significant operational challenges, including a near delisting from NASDAQ, despite the company's previous financial success during the pandemic [2][4][6]. Group 1: Company Background and Current Status - Sinovac Biotech, once known as the "king of vaccines," has managed to retain its NASDAQ listing after receiving approval from the NASDAQ Hearing Committee [2]. - The company faced a delisting decision two months prior, which was a result of its inability to submit timely financial reports due to internal conflicts [4][5]. - Sinovac's stock has been suspended for nearly seven years due to ongoing disputes over control, preventing the company from releasing financial statements [6][8]. Group 2: Internal Power Struggle - The internal conflict began in 2016 with the privatization of Sinovac, leading to a split between co-founders Yin Weidong and Pan Aihua, who have since formed opposing factions [10][11]. - The struggle intensified during the 2018 shareholder meeting, where Yin's board was opposed by Pan's faction, resulting in legal battles that have continued for years [10][12]. - A ruling from the UK Privy Council in January 2025 confirmed procedural flaws in the 2018 shareholder meeting, further complicating the internal governance [12][13]. Group 3: Financial Performance and Challenges - In 2021, Sinovac reported revenues of approximately RMB 128 billion and a net profit exceeding RMB 95.5 billion, largely due to the demand for COVID-19 vaccines [22]. - However, post-pandemic, the company's performance has declined sharply, with a projected revenue drop of 23.04% in 2024 and a net profit decrease of 66.36% [25]. - The company is also facing a significant cash outflow due to a proposed dividend plan totaling $7.448 billion (approximately RMB 53.8 billion), which could deplete its cash reserves and hinder future R&D efforts [26][27]. Group 4: Future Outlook - To avoid delisting, Sinovac must submit its 2024 annual report and 2025 interim report by May 11, 2025, which requires a legally recognized board to approve the financial statements [17][18]. - The ongoing internal conflict poses a risk to the company's governance and operational stability, making it imperative for Sinovac to establish a legitimate board to facilitate decision-making and strategic growth [28][29].

Core Viewpoint - The recent decision by the Nasdaq Hearing Committee allows Sinovac Biotech Ltd. to maintain its listing status on the Nasdaq Global Market, contingent upon the timely submission of financial reports by May 11, 2026 [5][6]. Group 1: Financial Reporting and Compliance - Sinovac must complete the submission of its annual financial report for the fiscal year ending December 31, 2024, and the interim financial report for the second quarter of 2025 by May 11, 2026 [6][7]. - The company has engaged Zhonghua Certified Public Accountants to conduct independent audits and is working collaboratively to meet the reporting requirements [7][8]. Group 2: Historical Performance and Challenges - Sinovac's revenue peaked in 2021 with a total revenue of 135.49 billion yuan, reflecting a year-on-year increase of 3694.36%, and a net profit of 59.21 billion yuan, up 7571.97% [9]. - However, the demand for COVID-19 vaccines has sharply declined, leading to significant revenue drops of 92.30% in 2022 and 69.97% in 2023, with net profits decreasing by 98.66% and 187.75% respectively [9]. Group 3: Product Pipeline and Market Expansion - Sinovac has a diverse product pipeline beyond COVID-19 vaccines, including vaccines for hepatitis A, influenza, varicella, and inactivated polio vaccines [9]. - Recent approvals for new products, such as the 23-valent pneumococcal polysaccharide vaccine, and successful bids for international orders, indicate a potential for growth in international markets [9]. Group 4: Governance Issues - Sinovac has faced ongoing internal governance challenges, stemming from a power struggle between co-founders, which has led to significant operational disruptions [10][11]. - The company has been under scrutiny for governance failures, resulting in its stock being suspended by Nasdaq in 2019 [12].

Core Viewpoint - The recent decision by the Nasdaq Hearing Committee allows SVA (Sinovac Biotech Ltd.) to maintain its listing status on the Nasdaq Global Market, contingent upon the timely submission of financial reports by May 11, 2026 [1][4]. Financial Reporting Requirements - Sinovac must complete the submission of its annual financial report for the fiscal year ending December 31, 2024, and the interim financial report for the second quarter of 2025 by May 11, 2026 [5][6]. - The company has engaged Zhonghua Certified Public Accountants to conduct independent audits and is working collaboratively to meet these reporting requirements [1][6]. Historical Context and Challenges - The delisting crisis began over two months ago when Sinovac received a delisting notice from Nasdaq due to its failure to submit the 20-F annual report by the extended deadline of November 11, 2025 [5][6]. - The company attributed the delay to the resignation of its previous independent auditor [5]. Financial Performance - Sinovac's revenue and profit have significantly declined since the peak of the COVID-19 vaccine demand, with revenues dropping by 92.30% in 2022 and 69.97% in 2023, and net profits decreasing by 98.66% and 187.75% respectively [7]. - In 2021, the company reported a record revenue of 135.49 billion yuan, a 3694.36% increase year-on-year, and a net profit of 59.21 billion yuan, a 7571.97% increase [7]. Product Pipeline and Market Opportunities - Sinovac has a diverse product pipeline beyond COVID-19 vaccines, including vaccines for hepatitis A, influenza, varicella, and inactivated polio vaccine [7]. - Recent approvals for new products, such as the 23-valent pneumococcal polysaccharide vaccine, and successful bids for international contracts, such as the exclusive influenza vaccine order in Chile, indicate potential growth in international markets [7]. Governance Issues - Sinovac has faced ongoing internal governance challenges, stemming from a power struggle between co-founders since 2016, which has led to significant operational disruptions [8][9]. - The company has been under scrutiny for governance failures, resulting in its stock being suspended by Nasdaq in 2019 [10].

Core Viewpoint - The recent decision by the Nasdaq Hearing Committee allows SVA (Sinovac Biotech Ltd.) to maintain its listing status on the Nasdaq Global Market, contingent upon the timely submission of financial reports by May 11, 2026 [1][3]. Group 1: Listing Status and Financial Reporting - Sinovac has been granted a reprieve from delisting, needing to submit its annual financial report for the year ending December 31, 2024, and the interim financial report for the second quarter of 2025 by May 11, 2026 [1][4]. - The company has engaged Zhonghua Certified Public Accountants to conduct independent audits and is working collaboratively to meet the reporting requirements [1][5]. Group 2: Historical Context and Financial Performance - The delisting crisis began over two months ago when Sinovac received a delisting notice from Nasdaq due to its failure to submit the required annual report on time [4][5]. - Sinovac's financial performance has drastically declined since its peak in 2021, with revenues dropping by 92.30% in 2022 and 69.97% in 2023, and net profits decreasing by 98.66% and 187.75% respectively [7]. Group 3: Product Pipeline and Market Opportunities - Despite the decline in COVID-19 vaccine demand, Sinovac has a diverse product pipeline, including vaccines for hepatitis A, influenza, varicella, and inactivated polio vaccine, with new products like the 23-valent pneumococcal polysaccharide vaccine recently approved [7]. - The company is also expanding into international markets, having secured a contract for influenza vaccines in Chile and obtaining WHO prequalification for some of its products [7]. Group 4: Internal Governance Issues - Sinovac has faced ongoing internal governance challenges, stemming from a power struggle between co-founders, which has led to significant operational disruptions and a history of stock trading halts due to governance failures [8]. - The company announced a substantial dividend plan of $7.448 billion, which could deplete over 70% of its cash reserves, raising concerns about its financial sustainability [8].